Загрузка...
An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
BACKGROUND: Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition to the development of leukemia. Patients with an interstitial deletion of C...
Сохранить в:
| Главные авторы: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Public Library of Science
2008
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2235894/ https://ncbi.nlm.nih.gov/pubmed/18271621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.0050035 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|